Floatz logo

Vobramitamab Duocarmazine

Carcinoma, Squamous Cell of Head and Neck

MacroGenicsPhase 2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
89/ 100

Competitive context

249 Active assets in the Carcinoma, Squamous Cell of Head and Neck cohort.

Asset / SponsorPhaseRating
Carboplatin
Akeso
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Vobramitamab Duocarmazine is also rated in:

melanomaDormant
CC
Indicative ·
44 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →